MedTrace Logo

Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients

NCT03408964 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-11-18

No results posted yet for this study

Summary

Participants to the study will be assigned to 7 cohorts according to the stage of disease and planned antitumor treatment at time of study entry.

In all patients, 12 ml of blood sample will be collected in EDTA tube for analysis of biological biomarkers in different time points.

Conditions

Interventions

OTHER

biological samples collection and analysis

Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule

Sponsors & Collaborators

  • Clinical Trial Unit Ente Ospedaliero Cantonale

    collaborator OTHER

  • Oncology Institute of Southern Switzerland

    lead OTHER

Principal Investigators

  • Ricardo Pereira Mestre, MD · Oncology Institute of Southern Switzerland (IOSI)

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03408964 on ClinicalTrials.gov